Methemoglobinemia in OR & ICU: Pathophysiology, Detection, and Management Review

Abstract

Methemoglobinemia represents a potentially life-threatening condition characterized by the oxidation of hemoglobin iron from the ferrous (Fe²⁺) to the ferric (Fe³⁺) state, impairing oxygen delivery to tissues. While rare, its occurrence in perioperative and intensive care settings demands urgent recognition and intervention due to the high risk of hypoxic injury. This review provides an in-depth analysis of methemoglobinemia, focusing on its pathophysiology, causative agents, clinical presentation, diagnostic challenges, and evidence-based management. Special emphasis is placed on high-risk scenarios in anesthesia and critical care, including the use of topical anesthetics, nitric oxide therapy, and antineoplastic agents such as those used in hepatocellular carcinoma. By integrating current literature with clinical guidelines, this article aims to enhance early detection and optimize treatment protocols to improve patient outcomes in acute care settings.

Introduction

Methemoglobinemia is a critical condition that can rapidly lead to severe tissue hypoxia if not promptly recognized and treated. In the operating room (OR) and intensive care unit (ICU), numerous pharmacological agents and clinical conditions predispose patients to this disorder. Unlike deoxyhemoglobin, methemoglobin cannot bind oxygen, and its presence shifts the oxygen dissociation curve leftward, further compromising oxygen release to tissues. The condition may be congenital, but acquired forms are more common in clinical practice, particularly following exposure to oxidizing drugs such as benzocaine, dapsone, or nitrites.

Hepatocellular carcinoma (HCC) patients receiving certain chemotherapeutic regimens are also at risk, as some antineoplastic agents can induce oxidative stress. Given the subtle early signs of methemoglobinemia, such as cyanosis unresponsive to oxygen therapy, chocolate-brown blood, and declining oxygen saturation despite adequate ventilation, clinicians must maintain a high index of suspicion. This review synthesizes current knowledge on methemoglobinemia, emphasizing its relevance in anesthesia and critical care, and provides a structured approach to diagnosis and management.

Pathophysiology of Methemoglobinemia

Under normal physiological conditions, hemoglobin contains iron in the ferrous state (Fe²⁺), which binds oxygen reversibly. Methemoglobinemia arises when oxidation converts Fe²⁺ to Fe³⁺, rendering hemoglobin incapable of oxygen transport. The body maintains methemoglobin levels below 1% through enzymatic reduction pathways, primarily via cytochrome b5 reductase (NADH-methemoglobin reductase). A secondary pathway involves NADPH-methemoglobin reductase, which requires an electron donor such as glutathione or methylene blue.

Exogenous oxidizing agents overwhelm these protective mechanisms, leading to pathological methemoglobin accumulation. Common triggers in the OR and ICU include local anesthetics (benzocaine, prilocaine), nitrates, sulfonamides, and nitric oxide. In patients with hepatocellular carcinoma, certain chemotherapeutic agents (e.g., sorafenib) may exacerbate oxidative stress, increasing susceptibility. Additionally, genetic deficiencies in cytochrome b5 reductase (Type I and II congenital methemoglobinemia) or hemoglobin M disease further predispose individuals to severe manifestations even with minimal oxidant exposure.

Etiology and Risk Factors in Perioperative and Critical Care Settings

Methemoglobinemia in hospitalized patients is predominantly acquired, with drug-induced cases being the most prevalent. Topical anesthetics, particularly benzocaine sprays used in endotracheal intubation or transesophageal echocardiography, are frequent culprits. Prilocaine, employed in regional anesthesia, can also induce methemoglobinemia, especially in high doses or in patients with impaired metabolism. Nitric oxide, used therapeutically for pulmonary hypertension, may increase methemoglobin levels, necessitating close monitoring.

ICU patients are at additional risk due to polypharmacy and comorbidities. Antibiotics such as dapsone and sulfamethoxazole-trimethoprim, commonly used for Pneumocystis pneumonia prophylaxis, possess strong oxidizing properties. Similarly, nitroglycerin and sodium nitroprusside, administered for hemodynamic management, can contribute to methemoglobin formation. Patients with hepatocellular carcinoma undergoing treatment with tyrosine kinase inhibitors (e.g., regorafenib) or immunotherapy may experience oxidative stress as a side effect, further complicating their clinical course.

Underlying conditions such as sepsis, acidosis, and G6PD deficiency amplify susceptibility by impairing reducing systems. Neonates and infants are particularly vulnerable due to immature cytochrome b5 reductase activity, while pregnant women exhibit increased sensitivity to oxidizing agents due to physiological changes in hemoglobin metabolism.

Clinical Presentation and Diagnostic Challenges

The clinical manifestations of methemoglobinemia depend on the methemoglobin fraction, ranging from asymptomatic to fatal circulatory collapse. Levels below 15% may cause mild symptoms such as headache, fatigue, and dizziness. Concentrations between 15-30% typically induce cyanosis, often described as "slate-gray," which does not improve with supplemental oxygen, a key distinguishing feature from other causes of hypoxemia.

Severe methemoglobinemia (>30%) leads to dyspnea, altered mental status, seizures, and metabolic acidosis due to tissue hypoxia. Levels exceeding 50% can precipitate coma, arrhythmias, and death. Notably, pulse oximetry becomes unreliable, often displaying a saturation plateau around 85% regardless of actual oxygenation. Co-oximetry is the gold standard for diagnosis, as it directly measures methemoglobin concentration.

A high clinical suspicion is essential, particularly in patients with unexplained hypoxia refractory to oxygen therapy. The characteristic chocolate-brown appearance of arterial blood (which does not turn red upon exposure to air) provides a crucial bedside clue. In patients with hepatocellular carcinoma receiving chemotherapy, new-onset cyanosis or hypoxia should prompt consideration of methemoglobinemia, especially if exposed to oxidizing medications.

Management Strategies in the OR and ICU

Immediate management hinges on discontinuing the offending agent and administering supplemental oxygen to maximize dissolved oxygen delivery. For symptomatic patients or methemoglobin levels >20%, methylene blue (1-2 mg/kg IV over 5 minutes) serves as the first-line antidote. It acts as an electron acceptor, facilitating the NADPH-dependent reduction of methemoglobin. Improvement should occur within 30-60 minutes, with repeat dosing if necessary.

Methylene blue is contraindicated in G6PD-deficient patients, as it may precipitate hemolysis. Alternative treatments include ascorbic acid (500 mg IV) or hyperbaric oxygen therapy in refractory cases. Exchange transfusion may be considered for life-threatening methemoglobinemia unresponsive to conventional therapy.

Prophylactic strategies involve minimizing exposure to high-risk agents in susceptible populations. For patients with hepatocellular carcinoma on oxidative therapies, baseline methemoglobin levels and G6PD status should be assessed. Continuous monitoring with co-oximetry is advisable in high-risk scenarios, particularly during prolonged anesthetic procedures or nitric oxide administration.

Prevention and Long-Term Considerations

Preventive measures are paramount in reducing the incidence of methemoglobinemia. In the OR, limiting the dose of topical anesthetics and avoiding benzocaine in high-risk patients can mitigate risk. Alternative local anesthetics such as lidocaine may be preferable. In the ICU, careful review of medication profiles to identify potential oxidizing agents is essential.

For patients with congenital methemoglobinemia or chronic acquired forms (e.g., due to dapsone therapy), long-term management may include riboflavin or ascorbic acid supplementation. Genetic counseling should be offered to families with hereditary forms. Survivors of severe episodes require follow-up for potential neurological sequelae secondary to prolonged hypoxia.

Conclusion

Methemoglobinemia remains a critical yet often overlooked cause of hypoxia in perioperative and intensive care settings. Early recognition, facilitated by understanding its unique clinical and laboratory features, is vital for timely intervention. Anesthesiologists and intensivists must remain vigilant, particularly when managing patients exposed to oxidizing drugs, including those with hepatocellular carcinoma on specific chemotherapies. Methylene blue remains the cornerstone of treatment, though alternative strategies must be considered in special populations. Through heightened awareness and systematic monitoring, the morbidity and mortality associated with this condition can be significantly reduced.

Read more such content on @ Hidoc Dr | Medical Learning App for Doctors